Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Hoppensteadt

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Seminars in Thrombosis and Hemostasis|September 30, 2000
Heparins in the new millennium: will unfractionated heparin survive? EpilogueJ Fareed, D A Hoppensteadt
Seminars in Thrombosis and Hemostasis|January 1, 1996
Pharmacology of the low-molecular-weight heparinsJ Fareed, D A Hoppensteadt
International Angiology : a Journal of the International Union of Angiology|June 18, 2014
Pharmacological profile of sulodexideD A Hoppensteadt, J Fareed
Seminars in Thrombosis and Hemostasis|October 1, 1989
In vitro protamine neutralization profiles of heparins differing in source and molecular weightA Racanelli, D A Hoppensteadt, J Fareed
Clinical Chemistry|September 23, 1997
Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugsD A Hoppensteadt, S Kahn, J Fareed
Die Pharmazie|November 1, 2001
Antithrombin and anti-Xa agents in the control of thrombogenesisJ Fareed, T Shaikh, D A Hoppensteadt
Thrombosis Research|August 1, 1995
Effect of protamine on heparin releasable TFPI antigen levels in normal volunteersD A Hoppensteadt, A Fasanella, J Fareed
Expert Opinion on Investigational Drugs|January 5, 2002
Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disordersB Kaiser, D A Hoppensteadt, J Fareed
Seminars in Thrombosis and Hemostasis|January 1, 1993
Current perspectives on low molecular weight heparinsJ Fareed, D A Hoppensteadt, J M Walenga
Seminars in Thrombosis and Hemostasis|April 1, 1985
Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractionsD A Hoppensteadt, J M Walenga, J Fareed
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Seminars in Thrombosis and Hemostasis|September 30, 2000
Heparins in the new millennium: will unfractionated heparin survive? EpilogueJ Fareed, D A Hoppensteadt
Seminars in Thrombosis and Hemostasis|January 1, 1996
Pharmacology of the low-molecular-weight heparinsJ Fareed, D A Hoppensteadt
International Angiology : a Journal of the International Union of Angiology|June 18, 2014
Pharmacological profile of sulodexideD A Hoppensteadt, J Fareed
Seminars in Thrombosis and Hemostasis|October 1, 1989
In vitro protamine neutralization profiles of heparins differing in source and molecular weightA Racanelli, D A Hoppensteadt, J Fareed
Clinical Chemistry|September 23, 1997
Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugsD A Hoppensteadt, S Kahn, J Fareed
Die Pharmazie|November 1, 2001
Antithrombin and anti-Xa agents in the control of thrombogenesisJ Fareed, T Shaikh, D A Hoppensteadt
Thrombosis Research|August 1, 1995
Effect of protamine on heparin releasable TFPI antigen levels in normal volunteersD A Hoppensteadt, A Fasanella, J Fareed
Expert Opinion on Investigational Drugs|January 5, 2002
Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disordersB Kaiser, D A Hoppensteadt, J Fareed
Seminars in Thrombosis and Hemostasis|January 1, 1993
Current perspectives on low molecular weight heparinsJ Fareed, D A Hoppensteadt, J M Walenga
Seminars in Thrombosis and Hemostasis|April 1, 1985
Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractionsD A Hoppensteadt, J M Walenga, J Fareed
Pageof 8